Page last updated: 2024-08-23

paclitaxel and Angiogenesis, Pathologic

paclitaxel has been researched along with Angiogenesis, Pathologic in 239 studies

Research

Studies (239)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's11 (4.60)18.2507
2000's101 (42.26)29.6817
2010's111 (46.44)24.3611
2020's16 (6.69)2.80

Authors

AuthorsStudies
Bai, R; Bastian, A; Choudhary, S; Gangjee, A; Hamel, E; Ihnat, MA; Pavana, RK1
Aguera, KN; Davis, GE; Griffin, CT; Kemp, SS; Koller, GM; Lin, PK; Salvador, J; Xie, J1
Abd-Alhaseeb, MM; Mahmoud, MA; Okda, TM; Omran, GA1
Niapour, A; Seyedasli, N1
Li, T; Li, XT; Li, XZ; Wang, XL; Wang, XW; Wang, XX; Yang, JC; Yang, ZY; Zhao, R; Zhao, XR1
Che, Z; Chen, D; Cui, J; Ding, K; Jiang, H; Li, A; Shu, Y; Xie, Z; Zhou, J; Zou, L1
Fan, C; Lee, BH; Mo, C; Shetti, D; Wei, K; Zhang, B1
Guan, J; Qian, J; Zhan, C1
Herrmann, R; Holzgrabe, U; Polednik, C; Roller, J; Schmidt, M; Skaf, J1
Español, AJ; Martínez Pulido, P; Salem, AR; Sales, ME; Sanchez, F; Sanchez, Y1
Abe, T; Akino, T; Alam, MT; Ameda, K; Annan, DA; Azuma, M; Dawood, RIH; Harabayashi, T; Hida, K; Hida, Y; Ishizuka, K; Kashiwagi, A; Kikuchi, H; Maishi, N; Maruyama, S; Matsumoto, R; Matsuno, Y; Miyajima, N; Morimoto, M; Osawa, T; Sato, M; Shinohara, N; Takeda, R; Tsuchiya, K; Yamashiro, K1
Cristofaro, I; Di Bari, M; Español, AJ; Salem, A; Sales, ME; Sanchez, Y; Tata, AM1
Bai, X; Bei, Y; Cheng, N; Shen, P; Shu, Y; Song, Y; Xu, L; Yang, N; Zhang, W1
Bian, Z; Liu, W; Liu, ZR; Mishra, F; Satyanarayana, G; Sharma, M; Sun, L; Turaga, RC; Yang, J; Yuan, Y1
Chen, SR; Chen, YF; Cheng, YB; Lin, YC; Wang, SW; Yen, JY; Yu, CL1
Annan, DA; Cong, L; Hida, K; Hida, Y; Maishi, N; Morimoto, H; Morimoto, M; Nam, JM; Young, MF1
Aguilar, MR; Martín-Hita, A; Palao-Suay, R; Riestra-Ayora, J; Sánchez-Rodríguez, C; Sanz-Fernández, R; Yanes-Díaz, J1
Andreucci, E; Barbato, G; Biagioni, A; Cianchi, F; Coratti, F; Giovannelli, L; Magnelli, L; Papucci, L; Peri, S; Schiavone, N; Staderini, F; Versienti, G1
Bianco, R; Cantile, M; Chambery, A; Cicatiello, V; Ciciola, P; Collina, F; D'Amato, V; De Falco, S; De Placido, S; Di Bonito, M; Di Mauro, C; Formisano, L; Marciano, R; Orsini, RC; Rosa, R; Servetto, A; Veneziani, BM1
Chen, S; Chen, X; Feng, Z; Li, J; Wu, X; Xu, J; Zhu, J1
Hu, Y; Jiang, T; Jin, K; Liu, X; Luo, Z; Pang, Z; Shen, S; Tuo, Y; Wang, L; Zhang, B1
Bijlsma, MF; Ebbing, EA; Krishnadath, KK; Mathôt, RAA; Medema, JP; Pistorius, MCM; Steins, A; van Laarhoven, HWM; Waasdorp, C; Wilmink, JW1
Cao, D; Lei, M; Liang, L; Sun, J; Sun, Z; Wang, M; Wei, Y; Xu, Y1
He, W; Li, S; Lv, Y; Xiao, Q; Yin, L; Zhao, X; Zhu, L1
Li, Y; Mi, X; Niu, J; Song, Z; Zhang, Y1
Alshangiti, A; Chandhoke, G; Ellis, PM1
Dong, W; Jin, D; Li, L; Liu, Y; Meng, Y; Wang, H; Xia, X; Yang, Y; Ye, J1
Barriuso, J; Berjón, A; Castelo, B; Crespo, R; Cruz, P; DE Molina, AR; Feliu, J; Hardisson, D; Heredia-Soto, V; Hernández, A; Herranz, J; Mendiola, M; Miguel-Martín, M; Peláez-García, A; Redondo, A; Yébenes, L1
Barra, F; Casarin, J; Ferrero, S; Ghezzi, F; Laganà, AS1
Cao, D; Huang, L; Kong, C; Li, H; Liang, L; Qin, H; Qu, X; Sun, Z; Wang, M; Wang, X; Xu, W; Yan, X; Zhang, Y1
Abdi, R; Annabi, N; Bahmani, B; Banouni, N; Bromberg, JS; Eskandari, SK; Greiner, DL; Ichimura, T; Jiang, L; Kasinath, V; Li, X; Ordikhani, F; Shultz, LD; Uehara, M1
Chow, A; Kerbel, RS; Khan, KA; Krüger, J; Man, S; Paez-Ribes, M; Pham, E; Wu, FTH; Xu, P1
Du, S; Lu, Y; Xiong, H; Xu, C; Yao, J1
Alsayed, A; He, C; Karginova, O; Lee, SS; Olopade, OI; Raoul, A; Weekley, CM; Wu, T1
Hayashi, K; Iwasaki, H; Kataoka, H; Kitagawa, M; Natsume, M; Okamoto, Y; Okuda, Y; Shimura, T1
Ishikura, N; Kurasawa, M; Sugimoto, M; Yamamoto, K; Yanagisawa, M; Yorozu, K1
Nannuru, KC; Nawandar, DM; Sharma, B; Singh, RK; Varney, ML1
Ahn, Y; Cho, HH; Hong, MH; Jeong, HY; Jeong, MH; Kang, WS; Kee, HJ; Kim, YS; Kwon, JS1
Alani, AW; Mishra, GP; Nguyen, D1
Alder, H; Baldassarre, G; Belletti, B; Califano, D; Canzonieri, V; Chiappetta, G; Cirombella, R; Croce, CM; Giglio, S; Losito, S; Lovat, F; Onesti, EC; Pellegrini, P; Pignata, S; Sonego, M; Sorio, R; Stoppacciaro, A; Vecchione, A; Volinia, S; Wernicke, D1
Chen, M; Duan, H; Jiang, Z; Miao, J; Sun, L; Wang, Y; Wu, M; Zhang, L; Zhang, S; Zhang, X; Zhu, X1
Artemov, D; Kato, Y; Zhu, W2
Becker, S; Gellrich, D; Strieth, S1
Chang, S; Liu, H; Pu, C; Sun, J; Wang, Z; Xu, RX; Zhu, S; Zhu, Y1
Brown, NJ; Reed, MW; Staton, CA; Woll, PJ; Young, RJ1
Aharon, A; Alishekevitz, D; Brenner, B; Bril, R; Fremder, E; Gingis-Velitski, S; Loven, D; Miller, V; Munster, M; Scherer, SJ; Shaked, Y; Voloshin, T1
Chen, J; Hu, Y; Jiang, X; Liao, Z; Mei, H; Pang, Z; Shen, S; Shi, W; Wang, H; Wang, Y; Yang, J; Zhang, B1
Chen, H; Chen, J; Feng, X; Gao, X; Hu, Q; Huang, M; Jiang, D; Jiang, X; Kang, T; Pang, Z; Song, Q; Yao, L; Zhang, X1
Saeki, T; Ueda, S1
Alama, A; Barletta, G; Biello, F; Boccardo, F; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Truini, A; Vanni, I1
Chen, Y; Fan, J; Fu, S; Lin, S; Sun, X; Wan, Q; Wu, Z; Yang, B; Yang, L; Zou, X1
Costa, VM; Diniz, C; Fresco, P; Soares, AS1
Angelucci, A; Botta, L; Calgani, A; Delle Monache, S; Sanità, P; Schenone, S1
Chen, P; Du, LC; Hu, HZ; Li, J; Li, YH; Luo, S; Tang, J; Wang, YS; Wei, YQ; Wen, YJ; Yang, DB; Zhang, P; Zhao, X1
Li, W; Wan, L; Wang, J; Zhai, LY1
Guo, F; He, S; Hu, Q; Jiang, W; Li, L; Lin, Z; Liu, X; Liu, Y; Ma, X; Sang, Y; Shen, G; Su, C; Wan, Y; Wang, Y; Wei, Y; Ye, T; Yin, T; Yu, M1
Augustin, HG; Besemfelder, E; Hu, J; Jugold, M; Kapel, SS; Korn, C; Pasparakis, M; Savant, S; Srivastava, K; Teichert, M; Thomas, M1
Chau, I; Smyth, EC; Tarazona, N1
Akiyama, K; Alam, MT; Hida, K; Hida, Y; Kawamoto, T; Maishi, N; Ohba, Y; Ohga, N; Ohmura, H; Shindoh, M; Torii, C; Yamada, K1
Han, J; Hou, G; Kong, Y; Nie, P; Sun, H; Yang, G1
Chen, HZ; Dong, X; Fang, C; Gao, YG; Guan, YY; Liu, HJ; Liu, YR; Lu, Q; Luan, X; Wang, C; Yang, SC1
Aslan, B; Calin, G; Dalton, HJ; Del C Monroig, P; Fernandez-de Thomas, RJ; Fuentes-Mattei, E; Gonzalez-Villasana, V; Ivan, C; Kahraman, N; Kanlikilicer, P; Lopez-Berestein, G; Ozpolat, B; Pradeep, S; Previs, RA; Rodriguez-Aguayo, C; Sood, AK; Velazquez-Torres, G; Wang, H1
Ancukiewicz, M; Duda, DG; Engelman, JA; Fidias, P; Gandhi, L; Heist, RS; Jain, RK; Lynch, TJ; Neal, JW; Pennell, NA; Sahani, DV; Sequist, LV; Shaw, AT; Temel, JS1
Hiura, K; Iwaki-Egawa, S; Komori, H; Shiraishi, A; Suzuki, C; Takamura, K; Watanabe, Y; Yamamoto, M1
Guo, P; Li, Z; Pan, W; Song, S; Tian, Y; Yang, X; Zheng, J1
Alishekevitz, D; Apte, RN; Benhar, M; Fremder, E; Isakov, E; Kaneti, L; Kaplanov, I; Machluf, M; Miller, V; Shaked, Y; Voloshin, T; Voronov, E1
Ann, DK; Arif, M; Chen, CH; Cheng, CT; Fong, LW; Wu, R; Yuan, Y; Zhai, J1
Chen, HZ; Fang, C; Gao, YG; Liu, HJ; Liu, YR; Luan, X; Wu, H; Yu, DH1
Al-Massarani, G; Alammar, M; Banat, I; Najjar, F1
Gao, H; He, Q; Liu, Y; Mei, L; Qiu, Y; Shi, K; Xu, C; Yang, Y; Yu, Q; Zhang, Q; Zhang, Z1
Gao, X; Gong, C; Huang, N; Men, K; Shi, H; Wang, B; Wei, X; Wei, Y; Wu, Q; Zheng, F1
Armaiz-Pena, GN; Coleman, RL; Dalton, HJ; Davis, AN; Hansen, JM; Langley, RR; Lin, YG; Merritt, WM; Nick, AM; Pradeep, S; Previs, RA; Sood, AK1
Choe, J; Han, M; Jeoung, D; Kim, H; Kim, Y; Kim, YM; Lee, H; Lee, YS; Park, D1
Castelo, B; Díaz, E; Espinosa, E; Fresno, JÁ; Gámez, A; Hardisson, D; Heredia, V; Herranz, J; Martínez-Marin, V; Mendiola, M; Miguel, M; Pinto, Á; Ramírez de Molina, A; Redondo, A; Yébenes, L; Zamora, P1
Bach, BA; Bamias, A; Brize, A; Coleman, RL; DeCensi, A; Fabbro, M; Fujiwara, K; Lhommé, C; Monk, BJ; Oaknin, A; Provencher, D; Raspagliesi, F; Ray-Coquard, I; Vergote, I; Vogl, FD; Zhang, K1
Bandyopadhyay, AK; Banerjee, I; Chattopadhyay, S; De, K; Dey, G; Ganguly, S; Gupta, A; Mandal, M; Misra, M; Mukherjee, D; Mukherjee, M1
Chen, HZ; Dong, X; Fang, C; Gao, YG; Guan, YY; Liu, HJ; Liu, YR; Lovell, JF; Lu, Q; Luan, X; Sun, P; Yang, SC; Zhao, M; Zheng, L1
Backen, A; Banks, RE; Berzuini, C; Clamp, A; Dive, C; Jayson, GC; Kaplan, R; Kristensen, GB; Pujade-Lauraine, E; Renehan, A; Scherer, SJ; Zhou, C1
Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S1
Chen, Z; Du, F; He, D; Jin, J; Li, H; Lu, H; Ma, X; Pan, Q; Tang, C; Wang, Y; Yao, X; Zang, X; Zhang, P1
Dou, Y; Sun, R; Tian, Z; Wei, H; Yue, T; Zheng, X1
Hu, Y; Jiang, T; Lu, H; Mei, H; Pang, Z; Shi, W; Wang, L; Zhang, B1
Chen, C; Huang, Z; Li, X; Su, F; Zhang, M1
Chen, Y; Gong, D; He, G; He, L; Jin, Q; Li, S; Song, X; Tan, X; Wu, J; Xu, B; Yang, L; Yu, T; Zeng, J1
Chen, J; Feng, J; Gao, X; Jiang, T; Kang, T; Wei, D; Wei, X; Yao, J; Zhu, Q1
Byakhov, M; Daeyaert, F; Gavrilova, E; Harrison, D; Joos, JB; Kochenkov, D; Peretolchina, N; Solomko, E; Stepanova, E; Tjulandin, S; Tsimafeyeu, I; Tyulyandina, A; Van Aken, K; Yin, W1
An, HJ; Heo, JH; Jeong, JY; Jung, SG; Kang, H; Kim, G; Kim, S; Kim, TH; Kwon, AY1
Berghaus, A; Dellian, M; Eichhorn, ME; Michaelis, U; Sauer, B; Strieth, S; Teifel, M; Werner, A1
Anthony, CT; Lyons, JM; Thomson, JL; Woltering, EA1
Collinson, F; Jayson, G1
Banik, NL; George, J; Ray, SK1
Gilbert, BE; Kline, K; Latimer, P; Menchaca, M; Sanders, BG; Snyder, RM; Yu, W1
Alì, G; Allegrini, G; Barletta, MT; Bocci, G; Bona, E; Coltelli, L; Danesi, R; Del Tacca, M; Falcone, A; Fioravanti, A; Fontanini, G; Giuntini, N; Orlandi, P1
Bohnenkamp, H; Bruns, CJ; Dellian, M; Eichhorn, ME; Guenzi, E; Ischenko, I; Jauch, KW; Luedemann, S; Michaelis, U; Papyan, A; Preissler, G; Strieth, S; Werner, A1
Aruga, T; Kuroi, K; Matsumoto, G; Muta, M; Nakashima, E; Sai, Y; Saji, S; Suzuki, E; Toi, M; Yanagawa, T1
Krylov, AL1
DiGiacomo, V; Granot, T; Levin, B; Meruelo, D; Tseng, JC1
Berndt, A; Cesca, M; D'Incalci, M; Frapolli, R; Giavazzi, R; Kosmehl, H; Richter, P; Ryan, AJ; Scarlato, V1
Jiang, H; Kanwar, JR; Pan, S; Sun, X; Tao, W; Zhang, M1
Allen, JK; Armaiz-Pena, GN; Coleman, RL; Jaffe, RB; Jennings, NB; Landen, CN; Lin, YG; Lu, C; Mangala, LS; Moreno-Smith, M; Nick, AM; Schmandt, R; Shahzad, MM; Sood, AK; Stone, RL1
Chen, HZ; Fang, C; Lu, Q; Xie, J; Yu, DH1
Chang, MC; Chen, CA; Chen, YL; Cheng, WF; Chiang, YC; Ho, CM; Hsieh, CY; Sun, WZ; Syu, MH1
Ho, PC; Wang, Z1
Bagnato, A; Cianfrocca, R; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F1
Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P1
Figg, WD; Gardner, ER; Kelly, M; Lee, KJ; Li, H; Moore, W; Springman, E1
Devineni, S; Ghebre, R; Ghosh, G; Jing, Y; Joshi, HP; Ramakrishnan, S; Subramanian, IV; Truskinovsky, AM1
Dafni, H; Hu, S; Larson, PE; Ronen, SM; Venkatesh, HS; Vigneron, DB; Wang, C; Ward, CS; Yoshihara, HA; Zhang, X1
Cheng, L; Hu, S; Huang, H; Ling, B; Liu, J; Shen, G; Song, L; Wei, W; Wu, Q; Xiao, W; Zhang, A; Zhao, T1
Chang, JS; Chen, CA; Chen, MW; Hsiao, M; Hsiao, SM; Kuo, ML; Lai, TC; Lo, CW; Rose-John, S; Wang, S; Wei, LH1
Eldar-Boock, A; Lupu, R; Miller, K; Sanchis, J; Satchi-Fainaro, R; Vicent, MJ1
Bai, C; Gu, A; Guo, S; Han, B; Jiang, L; Jin, X; Liu, W; Luo, Y; Shen, J; Wang, H; Xiu, Q; Zhang, Y; Zhao, Y; Zhou, J; Zhuang, Z1
Donahue, RN; McLaughlin, PJ; Zagon, IS1
Benayoun, L; Bril, R; Gingis-Velitski, S; Kerbel, RS; Man, S; Milsom, C; Munster, M; Shaked, Y; Voloshin, T1
Gupta, R; Krissansen, GW; Kuhn-Sherlock, B; Macgibbon, AK; Sun, X; Zhang, J1
Fukami, T; Hikita, S; Kondo, H; Kuroki, M; Miyamoto, S; Takahashi, Y; Tsujioka, H; Ueda, T; Yotsumoto, F1
Bryant, A; Gaitskell, K; Kehoe, S; Martinek, I; Morrison, J; Nicum, S1
Feenstra, K; Huang, Y; Jiang, W; Qian, CN; Resau, JH; Xue, C; Zhang, L; Zhao, HY; Zhao, YY1
Chen, S; Huang, Y; Luo, LM; Song, P; Wang, X; Yu, KF; Zhang, Q; Zhang, X; Zhao, BX; Zhao, Y1
Alessandri, G; Arnaldo, C; Bonomi, A; Cappelletti, G; Cartelli, D; Cavicchini, L; Ciusani, E; Coccè, V; Falchetti, ML; Ferrari, M; Invernici, G; Locatelli, A; Marfia, G; Navone, S; Pallini, R; Parati, E; Pessina, A; Sisto, F; Viganò, L1
Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II1
Breen, S; Chang, Y; Coats, S; Coffman, K; Czapiga, M; Fazenbaker, C; Gingles, N; Inigo, I; Jallal, B; Lavallee, T; Leow, CC; Peterson, N; Ricketts, SA; Soukharev, S; Woods, R1
Alitalo, K; Anttila, M; Hamalainen, K; Heinonen, S; Koponen, JK; Kosma, VM; Laidinen, S; Laurema, A; Sallinen, H; Sopo, M; Tuppurainen, L; Tuunanen, P; Yla-Herttuala, S1
Bookman, MA1
Chia, S; Lohmann, AE1
Dai, W; Li, RT; Liang, L; Lin, SW; Lu, JK; Xiang, Y; Yang, TY; Zhang, Q; Zhang, Y1
Carugati, E; Neri, D; Pasche, N; Pretto, F; Wulhfard, S1
Ali, A; Anbalagan, M; Bu, Y; Carrier, L; Hangauer, D; Jones, RK; Marsden, CG; Rowan, BG; Sheng, M1
Kaklamani, V; Raffin, M; Reddy, S1
Collinson, FJ; Perren, TJ; Seligmann, J1
Hall, KL; Rajput, S; Ran, S; Volk-Draper, LD; Wilber, A1
Abe, S; Araki, T; Fushimi, A; Higaki, K; Ishikawa, K; Kimura, T; Molema, G; Ogawara, K; Yoshizawa, Y1
Bhowmick, NA; Billet, S; Das, S; Fernandez, A; Fisher, PB; Kitada, S; Mitra, S; Noberini, R; Pasquale, EB; Pellecchia, M; Stebbins, JL; Wang, S; Wu, B; Zhang, Z1
Cronin, EB; DeFusco, PA; Hart, J; Hegde, PU; Kane, M; Ricci, A; Tannenbaum, SH; Tavakoli, B; Xu, Y; Zhu, Q1
Alessandri, G; Benetti, A; Bonomi, A; Caruso, A; Cavicchini, L; Ceccarelli, P; Ciusani, E; Coccè, V; Crovace, A; Falchetti, ML; Ferrari, M; Marfia, G; Navone, S; Parati, E; Pascucci, L; Pessina, A; Sisto, F; Zicari, S1
Bombardelli, E; Cassinelli, G; Cuccuru, G; Laccabue, D; Lanzi, C; Pratesi, G; Supino, R; Zuco, V; Zunino, F1
Alvarez, E; Faul, MM; Menon, K; Shih, C; Teicher, BA1
Baker, CH; Bucana, CD; Fidler, IJ; Kedar, D; McCarty, MF; Tsan, R; Weber, KL1
Agus, DB; Cordon-Cardo, C; Drobnjak, M; Fox, WD; Higgins, B; Maiese, KM; Scher, HI1
Bagnato, A; Cirilli, A; Muller, A; Natali, PG; Nicotra, MR; Salani, D; Simeone, P; Venuti, A1
Ashton, AW; Hotchkiss, KA; Mahmood, R; Russell, RG; Schwartz, EL; Sparano, JA1
Barrett, M; Burnitz, MC; Dipierro, C; Eto, M; Gibson, JJ; Myers, C; Phelps, C; Read, P; Somlyo, AP; Somlyo, AV1
Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C1
Kunstfeld, R; Michaelis, U; Naujoks, K; Petzelbauer, P; Teifel, M; Umek, W; Wickenhauser, G; Wolff, K1
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Salani, D; Spinella, F; Venuti, A1
Cao, Y; Han, R; Liu, HY; Wang, F; Xu, SF1
Dicker, AP; Grant, DS; Iliakis, G; Williams, TL1
Herbst, RS; Khuri, FR1
Klos, KS; Lee, S; Nagata, Y; Yang, W; Yu, D; Zhang, L; Zhou, X1
Dhar, DK; Fujiwaki, R; Hata, K; Ito, H; Miyazaki, K; Nagasue, N; Nakayama, K; Osaki, M1
Cao, Y; Fu, Z; Han, R; Liu, H; Wang, F; Zhao, W1
Bower, M; Gazzard, BG; Gotch, F; Hewitt, P; Mandalia, S; Nelson, M; Patterson, S; Portsmouth, S; Powles, T; Stebbing, J; Thirlwell, C; Wildfire, A1
Fidler, IJ; Herbst, RS; Isobe, T; Itasaka, S; Ki Hong, W; O'Reilly, MS; Onn, A; Wu, W1
Figg, WD; Ng, SS; Sparreboom, A1
Dahut, WL; Figg, WD; Retter, AS1
Dellian, M; Eichhorn, ME; Michaelis, U; Sauer, B; Schulze, B; Strieth, S; Teifel, M1
Albertsson, P; Damber, JE; Lennernäs, B; Norrby, K1
Brandwijk, RJ; Dings, RP; Griffioen, AW; Thijssen, VL1
Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG1
Gandara, D; Guo, L; Lau, D; Xue, L; Young, LJ1
Braguer, D; Briand, C; Camoin, L; Carré, M; Pasquier, E; Pourroy, B; Rebaï, O1
Carus, AP; Ferrero, A; Fuso, L; Jacomuzzi, ME; Mazzola, S; Ravarino, N; Sarotto, I; Sismondi, P; Spanu, PG; Zola, P1
Fidler, IJ; Kim, SJ; Lev, DC; Nam, DH; Onn, A; Price, JE; Stone, V; Yazici, S1
Atherton, JA; Baker, DA; Barth, W; Cohen, BD; Cooper, B; Dalvie, D; Hungerford, W; Kath, JC; Lin, J; Lyssikatos, JP; Moraski, G; Pollack, V; Ralston, S; Roberts, WG; Savage, D; Soderstrom, C; Soderstrom, E; Szewc, R; Tkalcevic, G; Ung, E; Wang, HF; Whalen, PM1
Braguer, D; Briand, C; Honore, S; Jordan, MA; Lehmann, M; Pasquier, E; Pourroy, B1
Grossman, A; Horwitz, SB; Keller, S; Lia, M; Lopez-Barcons, L; McDaid, HM; Pérez-Soler, R1
Bagnato, A; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F1
Lamph, WW; Yen, WC1
Bekele, BN; Bucana, CD; Fidler, IJ; Hawthorne, VS; Jasser, SA; Kim, SJ; Mandal, M; Myers, JN; Park, YW; Yazici, YD; Yigitbasi, OG; Younes, MN1
Busby, JE; Fan, D; Fidler, IJ; He, J; Kim, SJ; Thaker, P; Yazici, S; Yokoi, K1
Fujiwara, M; Hibi, K; Kodera, Y; Koike, M; Nakanishi, H; Nakao, A; Ohashi, N; Tatematsu, M; Yokoyama, H1
Corcoran, NM; Costello, AJ1
Gradishar, WJ1
Dong, C; Goldschmidt-Clermont, PJ; Hummers, L; Liu, X; Wang, T; Wigley, FM; Zhu, S1
Amino, N; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M1
Hattori, H; Hayashi, T; Ishihara, M; Ishizuka, T; Kikuchi, M; Maehara, T; Matsui, T; Nakamura, S; Obara, K; Ozeki, Y; Saito, Y; Takase, B; Yura, H1
Burt, HM; Gleave, J; Gleave, ME; Jackson, JK1
Liu, ZS; Sun, Q; Zhang, ZL1
Becker, S; Brix, G; Dellian, M; Eichhorn, ME; Griebel, J; Jauch, KW; Michaelis, U; Ruhstorfer, H; Sauer, B; Strieth, S; Teifel, M; Werner, A1
Schuch, G1
Ishiguro, Y; Kawakami, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M1
Freeze, BS; Goldberg, GL; Horwitz, SB; Huang, GS; Lopez-Barcons, L; McDaid, HM; Smith, AB1
Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M1
Bani, MR; Borsotti, P; Cassis, L; Eccles, SA; Garofalo, A; Giavazzi, R; Naumova, E; Riccardi, E; Scanziani, E; Ubezio, P1
Bouma-ter Steege, JC; Castermans, K; Dings, RP; Dirkx, AE; Griffioen, AW; Kwee, L; Mayo, KH; oude Egbrink, MG; Thijssen, VL; van der Schaft, DW; Wagstaff, J1
Fujita, M; Hattori, H; Ishihara, M; Kanatani, Y; Kikuchi, M; Maehara, T; Masuoka, K; Morimoto, Y; Nakamura, S; Obara, K; Takase, B1
Busby, JE; Do, KA; Fan, D; Fidler, IJ; He, J; Kim, SJ; Logothetis, C; Mathew, P; Maya, M; Nakamura, T; Uehara, H; Wang, X; Yazici, S1
Desai, N; Figg, WD; Kerbel, RS; Lee, C; Man, S; Ng, SS; Shaked, Y; Soon-Shiong, P; Sparreboom, A1
McGuire, WP1
Hou, M; Qiu, M; Yi, C1
Bonnar, J; D'Arcy, T; Laios, A; McGuinness, EP; O'Leary, JJ; O'Toole, SA; Sheppard, BL1
Baeuerle, PA; Clark, D; Freimark, B; Nickel, J; Pernasetti, F; Van Epps, D1
Burstein, HJ; Rugo, HS; Sledge, GW1
Herbst, R; Sandler, A; Vokes, E1
Isner, JM; Kirchmair, R; Kusano, K; Losordo, DW; Panagiotou, E; Ropper, AH; Schratzberger, P; Silver, M; Tietz, AB; Walter, DH; Weber, A; Weinberg, DH; Yoon, YS1
Bensussan, A; Bizzini, B; Gallo, RC; Genne, P; Larcier, P; Le Buanec, H; Paturance, S; Rad, FH; Ryffel, B; Uzan, G; Zagury, D1
Horiguchi, Y; Kikuchi, E; Kosaka, T; Kosugi, M; Miyajima, A; Murai, M1
Fujita, K; Ishiguro, Y; Kawakami, M; Kimura, M; Matsuda, H; Nishimura, G; Sano, D; Tsukuda, M; Yamashita, Y1
Feng, L; Garcia, GE; Jing, N; Mao, L; Weerasinghe, P; Yuan, P; Zhu, Q1
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F1
Dong, X; Jiang, H; Jiang, X; Krissansen, GW; Li, J; Sun, X; Xu, Z1
Bonezzi, K; Frapolli, R; Giavazzi, R; Kuhn, E; Martinelli, M; Riccardi, E; Ryan, AJ; Taraboletti, G; Zucchetti, M1
Han, ES; Monk, BJ1
Bai, CQ; Guo, HL; Song, YF; Wang, DT1
Marty, M; Pivot, X1
Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Sanborn, SL1
DeSesso, JM; Goeringer, GC; Scialli, AR1
Banquerigo, ML; Brahn, E; Oliver, SJ1
Arsenault, AL; Bains, SK; Burt, HM; Hunter, WL; Jackson, JK; Liggins, RT; Oktaba, AM1
Arsenault, LA; Burt, HM; Dordunoo, SK; Hunter, WL; Jackson, JK; Oktaba, AM1
Markman, M1
Herbst, RS; Takeuchi, H; Teicher, BA1
Arsenault, AL; Banquerigo, ML; Brahn, E; Hunter, WL; Lhoták, S1
Belotti, D; Borsotti, P; Drudis, T; Giavazzi, R; Pitelli, MR; Taraboletti, G; Vergani, V; Viale, G1
Bynon, S; Eckoff, D; Placidi, L; Scott, EC; Sommadossi, JP1
Appelt, K; Bloom, LA; Brekken, J; McDermott, CD; Shalinsky, DR; Varki, NM; Zook, S; Zou, H1
Hunter, NR; Mason, KA; Milas, L; Schimming, R1
Bianco, AR; Bianco, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Tortora, G1
Davis, DW; Dinney, CP; Hicklin, DJ; Inoue, K; Karashima, T; McConkey, DJ; Radinsky, R; Slaton, JW1
Albanese, C; Amanatullah, DF; Hulit, J; Lisanti, MP; Pestell, RG; Reutens, A; Rosen, E; Sparano, JA; Wang, C; Zafonte, BT1
Bruns, CJ; Davis, DW; Dinney, CP; Hicklin, DJ; Inoue, K; McConkey, DJ; Perrotte, P; Radinsky, R; Slaton, JW; Sweeney, P1
Hong, SD; Hong, SP; Kim, MJ; Kim, YY; Myoung, H1
Martin, C; Pan, J; Xu, G; Yeung, SC1
Fountzilas, G; Giatromanolaki, A; Kittas, C; Koukourakis, MI; Rigatos, S; Sivridis, E; Stathopoulos, GP; Vrettou, E1
Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A1
Chen, GA; Lorang, D; Nguyen, DM; Schrump, DS; Stewart, JH; Tabibi, E1
Dinney, CP; Inoue, K; Izawa, J; Karashima, T; Kedar, D; Kim, SJ; McConkey, DJ; Millikan, R; Perrotte, P; Shuin, T; Slaton, JW; Sweeney, P; Yoshikawa, C1
Favaudon, V; Hennequin, C1
Agata, N; Bamberg, M; Dickerson, WM; Fram, R; Kalluri, R; Kamphaus, GD; Kharbanda, S; Kufe, D; Milhollen, M; Reimer, CL; Rook, SL; Tammam, JG1
Blanchard, JM1
Baccarini, S; Bacigalupo, I; Barillari, G; Bugarini, R; Bussolino, F; Cafaro, A; Carlei, D; Ensoli, B; Falchi, M; Leone, P; Malavasi, L; Monini, P; Palladino, C; Rezza, G; Sgadari, C; Toschi, E; Valdembri, D1
Burke, P; Gandour-Edwards, R; Guo, L; Lau, D; Lo, SH1
Douillard, JY1
Dinney, CP; Fan, Z; Hicklin, DJ; Izawa, JI; Karashima, T; Kedar, D; Kim, SJ; Pettaway, C; Shuin, T; Slaton, JW; Sweeney, P1
Abbruzzes, J; Azhdarinia, A; Bryant, JL; Fogler, WE; Herbst, R; Kalimi, SK; Kim, EE; Kim, KD; Ozaki, K; Podoloff, DA; Roach, JS; Schechter, NR; Wu, P; Yang, DJ; Yu, DF1
Larsson, LI; Lichtenberg, J1
Bengtsson, NO; Blomqvist, C; Heikkilä, R; Malmström, P; Ostenstad, B; Paavonen, T; Saksela, E; Sjöström, J; Tynninen, O; Valvere, V; von Boguslawski, K; Wist, E1

Reviews

20 review(s) available for paclitaxel and Angiogenesis, Pathologic

ArticleYear
Antiangiogenic therapies in non-small-cell lung cancer.
    Current oncology (Toronto, Ont.), 2018, Volume: 25, Issue:Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel

2018
Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review.
    Gynecologic and obstetric investigation, 2019, Volume: 84, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Female; Humans; Indoles; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel

2019
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Indoles; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases

2014
Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
    Immunotherapy, 2014, Volume: 6, Issue:11

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Approval; Humans; Hypertension; Immunotherapy; Neovascularization, Pathologic; Neutropenia; Paclitaxel; Ramucirumab; Randomized Controlled Trials as Topic; Stomach Neoplasms; Vascular Endothelial Growth Factor Receptor-2

2014
New therapeutic agents in ovarian cancer.
    Current opinion in obstetrics & gynecology, 2009, Volume: 21, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Drug Administration Routes; ErbB Receptors; Female; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly Adenosine Diphosphate Ribose; Protein Kinase Inhibitors; Proteins; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A

2009
[Experience in using stents with an antiproliferative coating in treatment of stenoses and occlusions of coronary arteries. Review of the literature].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2008, Volume: 14, Issue:4

    Topics: Coronary Stenosis; Coronary Vessels; Drug-Eluting Stents; Humans; Immunosuppressive Agents; Neovascularization, Pathologic; Paclitaxel; Prosthesis Design; Sirolimus; Treatment Outcome

2008
Angiogenesis inhibitors for the treatment of ovarian cancer.
    The Cochrane database of systematic reviews, 2011, Sep-07, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Indoles; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Survival Analysis

2011
First-line chemotherapy in epithelial ovarian cancer.
    Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:1

    Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A

2012
Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?
    Current treatment options in oncology, 2012, Volume: 13, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cardiotoxins; Disease-Free Survival; Female; Humans; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A

2012
Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents.
    Current oncology reports, 2012, Volume: 14, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Meta-Analysis as Topic; Neoadjuvant Therapy; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel

2012
Mode of action of docetaxel - a basis for combination with novel anticancer agents.
    Cancer treatment reviews, 2003, Volume: 29, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Follow-Up Studies; Humans; Male; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pharmacogenetics; Survival Analysis; Taxoids; Treatment Outcome

2003
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
    Clinical prostate cancer, 2003, Volume: 2, Issue:3

    Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Cyclohexanes; Humans; Male; Minocycline; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Prostatic Neoplasms; Sesquiterpenes

2003
Chitosan hydrogel as a drug delivery carrier to control angiogenesis.
    Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2006, Volume: 9, Issue:1

    Topics: Animals; Biocompatible Materials; Chitosan; Cross-Linking Reagents; Drug Delivery Systems; Fibroblast Growth Factor 2; Hydrogels; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Occlusive Dressings; Paclitaxel; Rabbits; Ultraviolet Rays; Wound Healing

2006
The role of angiogenesis inhibition in the treatment of breast cancer.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:10 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A

2006
Angiogenesis inhibition in the treatment of lung cancer.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:11 Suppl 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A

2006
Bevacizumab in the treatment of ovarian cancer.
    Expert review of anticancer therapy, 2007, Volume: 7, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Hematologic Diseases; Humans; Intestinal Perforation; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Salvage Therapy; Vascular Endothelial Growth Factor A

2007
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:7

    Topics: Angiogenesis Inhibitors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Taxoids; Vascular Endothelial Growth Factor A

2008
Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.
    Frontiers in bioscience : a journal and virtual library, 2000, Dec-01, Volume: 5

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Databases, Factual; Enzyme Inhibitors; Flavonoids; Humans; Microtubule-Associated Proteins; Neovascularization, Pathologic; Oncogenes; Paclitaxel; Piperidines; Receptors, Estrogen; Tamoxifen; Transforming Growth Factor beta; Trastuzumab; Tumor Suppressor Proteins

2000
[Molecular mechanisms of oncogenic transformation: what's new?].
    Bulletin du cancer, 2002, Volume: 89, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Disease Progression; Drug Resistance; Fusion Proteins, bcr-abl; Humans; Mice; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Neural Cell Adhesion Molecules; Paclitaxel; Protein Serine-Threonine Kinases; Radiation Tolerance; Rats; Thrombospondins; Transforming Growth Factor beta; Tuberous Sclerosis

2002
[New prospects in the treatment of non-small-cell lung carcinoma (NSCLC): new biological factors].
    Revue de pneumologie clinique, 2001, Volume: 57, Issue:5 Pt 2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Female; Humans; Lung Neoplasms; Metalloendopeptidases; Neovascularization, Pathologic; Organic Chemicals; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Research; Time Factors

2001

Trials

10 trial(s) available for paclitaxel and Angiogenesis, Pathologic

ArticleYear
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Feb-03, Volume: 112, Issue:5

    Topics: Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A

2015
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Placebo Effect; Quality of Life; Recombinant Fusion Proteins; Treatment Outcome

2016
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab.
    British journal of cancer, 2016, Jul-12, Volume: 115, Issue:2

    Topics: Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bevacizumab; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptor, TIE-2

2016
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Endostatins; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Recombinant Proteins; Treatment Outcome

2011
Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anthracyclines; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Disease Progression; Female; Fibroblast Growth Factor 2; Humans; Interleukin-6; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Sarcoma, Kaposi; Skin Neoplasms; Time Factors; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2003
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
    International journal of cancer, 2005, Jan-20, Volume: 113, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Humans; In Vitro Techniques; Isoenzymes; Laminin; Lung; Male; Melanoma; Membrane Proteins; Neovascularization, Pathologic; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteoglycans; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Cells, Cultured; Umbilical Veins

2005
In focus: non-small cell lung cancer: E1505.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Humans; Lung Neoplasms; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A

2007
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
    Investigational new drugs, 2008, Volume: 26, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Thalidomide

2008
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:6

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured

2001
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
    British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Methotrexate; Neovascularization, Pathologic; Paclitaxel; Prognosis; Taxoids; Time Factors; Treatment Outcome

2002

Other Studies

209 other study(ies) available for paclitaxel and Angiogenesis, Pathologic

ArticleYear
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
    Bioorganic & medicinal chemistry, 2017, 01-15, Volume: 25, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microtubules; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship

2017
Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents.
    The American journal of pathology, 2021, Volume: 191, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Cells, Cultured; Docetaxel; Endothelial Cells; Endothelium, Vascular; Epothilones; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred C57BL; Morphogenesis; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel

2021
Rosmarinic acid suppresses inflammation, angiogenesis, and improves paclitaxel induced apoptosis in a breast cancer model via NF3 κB-p53-caspase-3 pathways modulation.
    Journal of applied biomedicine, 2021, Volume: 19, Issue:4

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cinnamates; Depsides; Inflammation; Mice; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Paclitaxel; Rosmarinic Acid; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A

2021
Acquisition of paclitaxel resistance modulates the biological traits of gastric cancer AGS cells and facilitates epithelial to mesenchymal transition and angiogenesis.
    Naunyn-Schmiedeberg's archives of pharmacology, 2022, Volume: 395, Issue:5

    Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Neovascularization, Pathologic; Paclitaxel; Stomach Neoplasms

2022
YAP inhibitor verteporfin suppresses tumor angiogenesis and overcomes chemoresistance in esophageal squamous cell carcinoma.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10

    Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neovascularization, Pathologic; Paclitaxel; Verteporfin

2023
JP1 normalizes tumor vasculature to suppress metastasis and facilitate drug delivery by inhibiting IL-8.
    JCI insight, 2023, 06-22, Volume: 8, Issue:12

    Topics: Humans; Interleukin-8; Neoplasms; Neovascularization, Pathologic; Oxygen; Paclitaxel; Tumor Microenvironment

2023
Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Cells, 2019, 08-14, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Female; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Triple Negative Breast Neoplasms; Wnt Signaling Pathway

2019
Preparation of Cholera Toxin Subunit B Functionalized Nanoparticles for Targeted Therapy of Glioblastoma.
    Methods in molecular biology (Clifton, N.J.), 2020, Volume: 2059

    Topics: Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Cholera Toxin; Drug Carriers; Glioblastoma; Glycosphingolipids; Microscopy, Electron, Transmission; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer

2020
Anticancer effects of NSC‑631570 (Ukrain) in head and neck cancer cells: In vitro analysis of growth, invasion, angiogenesis and gene expression.
    Oncology reports, 2020, Volume: 43, Issue:1

    Topics: Antineoplastic Agents; Berberine Alkaloids; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Paclitaxel; Phenanthridines

2020
Effect of low dose metronomic therapy on MCF-7 tumor cells growth and angiogenesis. Role of muscarinic acetylcholine receptors.
    International immunopharmacology, 2020, Volume: 84

    Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbachol; Cell Line; Cell Proliferation; Cell Survival; Cholinergic Agonists; Drug Interactions; Female; Humans; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Receptors, Muscarinic

2020
Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome.
    Cancer research, 2020, 07-15, Volume: 80, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Induction Chemotherapy; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays

2020
The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
    PloS one, 2020, Volume: 15, Issue:9

    Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arecoline; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbachol; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholinergic Agonists; Down-Regulation; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptor, Muscarinic M2; RNA, Small Interfering; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2020
B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
    Biochemical pharmacology, 2021, Volume: 183

    Topics: Animals; Antineoplastic Agents, Phytogenic; B7 Antigens; Biomarkers, Tumor; Drug Delivery Systems; Female; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; RAW 264.7 Cells; Triple Negative Breast Neoplasms; Tumor Microenvironment; Tumor-Associated Macrophages

2021
Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC.
    The Journal of experimental medicine, 2021, 04-05, Volume: 218, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cancer-Associated Fibroblasts; Cell Line, Tumor; Doxorubicin; Endothelial Cells; Female; Humans; Hypoxia; Integrin alphaVbeta3; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Protein-Lysine 6-Oxidase; Signal Transduction; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays

2021
Additional alkaloids from Zoanthus vietnamensis with neuroprotective and anti-angiogenic effects.
    Bioorganic chemistry, 2021, Volume: 109

    Topics: Alkaloids; Animals; Anthozoa; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Discovery; Ganglia, Spinal; Humans; Mice; Molecular Structure; Neovascularization, Pathologic; Neurons; Paclitaxel; Stem Cells

2021
Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
    Breast cancer research : BCR, 2021, 05-10, Volume: 23, Issue:1

    Topics: Angiopoietin-2; Animals; Biglycan; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Fibrosis; Humans; Mice; Mice, Knockout; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prognosis; Signal Transduction; Stromal Cells; Treatment Outcome; Tumor Microenvironment; Tumor Necrosis Factor-alpha

2021
Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma:
    Drug delivery, 2021, Volume: 28, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Carriers; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Polymers; Squamous Cell Carcinoma of Head and Neck; Tumor Burden; Xenograft Model Antitumor Assays

2021
Enhanced Vasculogenic Capacity Induced by 5-Fluorouracil Chemoresistance in a Gastric Cancer Cell Line.
    International journal of molecular sciences, 2021, Jul-19, Volume: 22, Issue:14

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endothelial Cells; Fluorouracil; Humans; Neovascularization, Pathologic; Paclitaxel; Stomach Neoplasms; Thalidomide; Thymidine Phosphorylase; Up-Regulation

2021
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
    British journal of cancer, 2017, May-23, Volume: 116, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biphenyl Compounds; Cell Proliferation; Coculture Techniques; Endothelial Cells; Female; Gene Silencing; Hedgehog Proteins; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Pyridines; RNA, Messenger; Signal Transduction; Thrombospondin 1; Tissue Array Analysis; Transfection; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult; Zinc Finger Protein GLI1

2017
Taxol alleviates collagen-induced arthritis in mice by inhibiting the formation of microvessels.
    Clinical rheumatology, 2019, Volume: 38, Issue:1

    Topics: Animals; Arthritis, Experimental; Disease Models, Animal; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Paclitaxel; Synovial Membrane; Vascular Endothelial Growth Factor A

2019
Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice.
    Scientific reports, 2017, 08-30, Volume: 7, Issue:1

    Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Drug Delivery Systems; Drug Synergism; Drug Therapy, Combination; Gene Expression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Micelles; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Polyesters; Polyethylene Glycols; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays

2017
Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.
    Drug delivery, 2017, Volume: 24, Issue:1

    Topics: Albumins; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2017
Tumor associated macrophages and angiogenesis dual-recognizable nanoparticles for enhanced cancer chemotherapy.
    Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:3

    Topics: Animals; Annexin A1; Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; Drug Delivery Systems; Humans; Macrophages; Mice; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays

2018
Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis.
    Theranostics, 2018, Volume: 8, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Caseins; Cell Line, Tumor; Drug Liberation; Female; Hyaluronic Acid; Hydroxamic Acids; Mammary Neoplasms, Experimental; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Nanoconjugates; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prodrugs; Protein Binding

2018
Cripto-1 promotes resistance to drug-induced apoptosis by activating the TAK-1/NF-κB/survivin signaling pathway.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 104

    Topics: Apoptosis; Carcinogenesis; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; GPI-Linked Proteins; HEK293 Cells; Humans; Inhibitor of Apoptosis Proteins; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase Kinases; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Paclitaxel; Signal Transduction; Survivin

2018
Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle.
    Journal of controlled release : official journal of the Controlled Release Society, 2018, 10-10, Volume: 287

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Drug Delivery Systems; Female; Gene Transfer Techniques; Human Umbilical Vein Endothelial Cells; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Micelles; Neovascularization, Pathologic; Paclitaxel; Polyesters; Polyethylene Glycols; RNA, Small Interfering; RNAi Therapeutics; Vascular Endothelial Growth Factor A

2018
Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Anticancer research, 2018, Volume: 38, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Clinical Decision-Making; Cytoreduction Surgical Procedures; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; ROC Curve; Transcriptome

2018
PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer.
    Drug delivery, 2018, Volume: 25, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Programmed Cell Death 1 Receptor; Regional Blood Flow; Survival Analysis; Tissue Distribution

2018
Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.
    EBioMedicine, 2018, Volume: 38

    Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line; Disease Models, Animal; Endothelium, Lymphatic; Female; Humans; Immunohistochemistry; Lymph Nodes; Male; Mice; Molecular Targeted Therapy; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Theranostic Nanomedicine; Xenograft Model Antitumor Assays

2018
Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease.
    British journal of cancer, 2019, Volume: 120, Issue:2

    Topics: Animals; B7-H1 Antigen; Bevacizumab; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Immunotherapy; Kidney Neoplasms; Mammary Neoplasms, Animal; Mice; Neoadjuvant Therapy; Neovascularization, Pathologic; Paclitaxel; Sunitinib

2019
Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines.
    Biomaterials science, 2019, Feb-26, Volume: 7, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Cell Survival; Deoxycytidine; Gemcitabine; Hep G2 Cells; Heparin, Low-Molecular-Weight; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Liver Neoplasms; Mice; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Transplantation, Heterologous

2019
Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis.
    Molecular cancer therapeutics, 2019, Volume: 18, Issue:5

    Topics: Animals; Apoptosis; Benzothiazoles; Bromobenzenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Copper; Copper Transport Proteins; Copper-Transporting ATPases; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Chaperones; Molybdenum; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Small Molecule Libraries; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays

2019
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Placenta Growth Factor; Ramucirumab; Retrospective Studies; Stomach Neoplasms

2019
Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
    Oncology reports, 2019, Volume: 42, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Proliferation; Doxorubicin; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019
Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Paclitaxel; Receptors, Interleukin-8B; Tumor Burden

2013
Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model.
    Atherosclerosis, 2013, Volume: 228, Issue:2

    Topics: Administration, Oral; Angioplasty, Balloon; Animals; Aorta; Aortic Diseases; Apoptosis; Blood Glucose; Cilostazol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Drug-Eluting Stents; Endothelial Cells; Intercellular Adhesion Molecule-1; Male; Neovascularization, Pathologic; Paclitaxel; Phosphodiesterase 3 Inhibitors; Prosthesis Design; Rats; Rats, Sprague-Dawley; Tetrazoles; Thrombosis; Time Factors; Vascular Cell Adhesion Molecule-1; von Willebrand Factor; Wound Healing

2013
Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade.
    Molecular pharmaceutics, 2013, May-06, Volume: 10, Issue:5

    Topics: Angiogenesis Inhibitors; Apoptosis; Cell Movement; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Micelles; Neovascularization, Pathologic; Paclitaxel; Particle Size; Polyethylene Glycols; Sirolimus

2013
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Jun-11, Volume: 110, Issue:24

    Topics: Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Coculture Techniques; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-2

2013
Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
    The international journal of biochemistry & cell biology, 2013, Volume: 45, Issue:8

    Topics: Amides; Angiogenesis Inhibitors; Animals; Blood Vessels; Cell Cycle; Cell Movement; Cell Proliferation; Chickens; Chorioallantoic Membrane; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Drugs, Chinese Herbal; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Male; Mice, Nude; Microtubules; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Podophyllotoxin; Pyridines; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays

2013
Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.
    Magma (New York, N.Y.), 2014, Volume: 27, Issue:2

    Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Artifacts; Bevacizumab; Body Water; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Imaging; MCF-7 Cells; Mice; Mice, SCID; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome

2014
Static magnetic fields increase tumor microvessel leakiness and improve antitumoral efficacy in combination with paclitaxel.
    Cancer letters, 2014, Feb-01, Volume: 343, Issue:1

    Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Models, Animal; Endothelial Cells; Leukocytes; Magnetic Fields; Male; Mesocricetus; Microcirculation; Microscopy, Fluorescence; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Permeability

2014
Ultrasound-mediated destruction of LHRHa-targeted and paclitaxel-loaded lipid microbubbles for the treatment of intraperitoneal ovarian cancer xenografts.
    Molecular pharmaceutics, 2014, Jan-06, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Drug Delivery Systems; Female; Humans; Immunoenzyme Techniques; Injections, Intraperitoneal; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptors, LHRH; Tumor Cells, Cultured; Ultrasonics; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2014
Vascular-targeted agents for the treatment of angiosarcoma.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Axitinib; Bevacizumab; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Movement; Doxorubicin; Everolimus; Hemangiosarcoma; Humans; Imidazoles; Indazoles; Neovascularization, Pathologic; Paclitaxel; Protein Array Analysis; Sirolimus; Vascular Endothelial Growth Factor A

2014
Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.
    International journal of cancer, 2014, Jul-15, Volume: 135, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Female; Flow Cytometry; Gene Knockdown Techniques; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Osteopontin; Paclitaxel

2014
Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Albumins; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Contrast Media; Female; Gadolinium DTPA; Humans; Magnetic Resonance Angiography; Mice; Mice, SCID; Neovascularization, Pathologic; Paclitaxel; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma.
    Biomaterials, 2014, Volume: 35, Issue:13

    Topics: Animals; Cell Line; Drug Delivery Systems; Glioma; Green Fluorescent Proteins; Human Umbilical Vein Endothelial Cells; Humans; In Situ Nick-End Labeling; Mice; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Recombinant Fusion Proteins

2014
iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas.
    Biomaterials, 2014, Volume: 35, Issue:14

    Topics: Administration, Intravenous; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Collagen; Coumarins; Drug Combinations; Endocytosis; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Kaplan-Meier Estimate; Lactic Acid; Laminin; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proteoglycans; Rats; Rats, Sprague-Dawley; Spectroscopy, Near-Infrared; Thiazoles; Tissue Distribution; Treatment Outcome

2014
Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy.
    Breast cancer (Tokyo, Japan), 2014, Volume: 21, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Hemoglobins; Humans; Mammary Glands, Human; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Spectrophotometry, Infrared; Triple Negative Breast Neoplasms; Vascular Remodeling

2014
Thermosensitive hydrogel used in dual drug delivery system with paclitaxel-loaded micelles for in situ treatment of lung cancer.
    Colloids and surfaces. B, Biointerfaces, 2014, Oct-01, Volume: 122

    Topics: Antineoplastic Agents, Phytogenic; Cell Proliferation; Drug Delivery Systems; Hydrogels; Lung Neoplasms; Micelles; Neovascularization, Pathologic; Paclitaxel; Particle Size

2014
The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Adenosine; Animals; Antineoplastic Agents; Cell Physiological Phenomena; Disease Progression; Drug Screening Assays, Antitumor; Humans; Inosine; Melanoma; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Receptor, Adenosine A3; Tumor Cells, Cultured

2014
Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis.
    Experimental cell research, 2014, Oct-15, Volume: 328, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Humans; Immunoenzyme Techniques; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; src-Family Kinases; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2

2014
Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.
    Cancer science, 2014, Volume: 105, Issue:11

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemokine CCL21; Cytokines; Cytotoxicity, Immunologic; Disease Models, Animal; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Melanoma, Experimental; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Tumor Burden

2014
Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.
    International journal of molecular sciences, 2014, Oct-23, Volume: 15, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2014
Extravascular red blood cells and hemoglobin promote tumor growth and therapeutic resistance as endogenous danger signals.
    Journal of immunology (Baltimore, Md. : 1950), 2015, Jan-01, Volume: 194, Issue:1

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Erythrocytes; Hemoglobins; Hemorrhage; Inflammation; Interleukin-1beta; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Reactive Oxygen Species; Transcription Factor RelA; Tumor Microenvironment

2015
Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
    Cancer cell, 2014, Dec-08, Volume: 26, Issue:6

    Topics: Adjuvants, Pharmaceutic; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Endothelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays

2014
Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel.
    The American journal of pathology, 2015, Volume: 185, Issue:2

    Topics: Administration, Metronomic; Animals; Anti-Arrhythmia Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Verapamil; Xenograft Model Antitumor Assays

2015
MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Female; Humans; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Peptides, Cyclic; Polyethylene Glycols; Positron-Emission Tomography; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays

2015
Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Biomaterials, 2015, Volume: 42

    Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Movement; Cell Survival; Collagen; Coumarins; Drug Combinations; Drug Delivery Systems; Endocytosis; Female; Human Umbilical Vein Endothelial Cells; Humans; Intracellular Signaling Peptides and Proteins; Laminin; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Nanomedicine; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Proteoglycans; Rats, Sprague-Dawley; Subcutaneous Tissue; Thiazoles; Xenograft Model Antitumor Assays

2015
Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, May-01, Volume: 21, Issue:9

    Topics: Albumins; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Diphosphonates; Female; High-Throughput Screening Assays; Humans; Imidazoles; Immunohistochemistry; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; p21-Activated Kinases; p38 Mitogen-Activated Protein Kinases; Paclitaxel; rac1 GTP-Binding Protein; Signal Transduction; Transfection; Xenograft Model Antitumor Assays; Zoledronic Acid

2015
MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
    Cancer biomarkers : section A of Disease markers, 2015, Volume: 15, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Neutrophils; Paclitaxel; Platinum; Vascular Endothelial Growth Factor A

2015
In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
    International journal of pharmaceutics, 2015, Volume: 486, Issue:1-2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Humans; Male; Mice; Micelles; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyethylene Glycols; Polyglactin 910; Tissue Distribution; Tumor Burden

2015
Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Macrophages; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Receptors, Interleukin-1; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Burden

2015
Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment.
    Oncotarget, 2015, Jun-20, Volume: 6, Issue:17

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Intracellular Signaling Peptides and Proteins; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Myristoylated Alanine-Rich C Kinase Substrate; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Phosphorylation; RNA Interference; RNA, Small Interfering; Tubulin Modulators

2015
IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
    Bioconjugate chemistry, 2015, Aug-19, Volume: 26, Issue:8

    Topics: Animals; Annexin A1; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays

2015
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
    The International journal of biological markers, 2015, Nov-11, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2015
Multifunctional Tandem Peptide Modified Paclitaxel-Loaded Liposomes for the Treatment of Vasculogenic Mimicry and Cancer Stem Cells in Malignant Glioma.
    ACS applied materials & interfaces, 2015, Aug-05, Volume: 7, Issue:30

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Glioma; Liposomes; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Treatment Outcome

2015
Combined Delivery and Anti-Cancer Activity of Paclitaxel and Curcumin Using Polymeric Micelles.
    Journal of biomedical nanotechnology, 2015, Volume: 11, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Curcumin; Drug Carriers; Drug Delivery Systems; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Micelles; Microcirculation; Microscopy, Fluorescence; Neovascularization, Pathologic; NF-kappa B; Paclitaxel; Polymers; Zebrafish

2015
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:12

    Topics: Administration, Metronomic; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays

2015
miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
    Oncotarget, 2016, Mar-01, Volume: 7, Issue:9

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neovascularization, Pathologic; Paclitaxel; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2016
Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel.
    Oncotarget, 2016, Apr-26, Volume: 7, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate

2016
Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy.
    Acta biomaterialia, 2016, 07-01, Volume: 38

    Topics: Animals; Cell Line, Tumor; Drug Carriers; Glioma; Lipids; Mice; Nanoparticles; Neovascularization, Pathologic; NIH 3T3 Cells; Octreotide; Paclitaxel; Rats

2016
Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel.
    Biomaterials, 2016, Volume: 95

    Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Delivery Systems; Female; Heterografts; Humans; Lactates; Mice; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyethylene Glycols; Tumor Microenvironment

2016
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    British journal of cancer, 2016, 08-09, Volume: 115, Issue:4

    Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays

2016
Chemotherapy enhances tumor vascularization via Notch signaling-mediated formation of tumor-derived endothelium in breast cancer.
    Biochemical pharmacology, 2016, Oct-15, Volume: 118

    Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Bridged-Ring Compounds; Doxorubicin; Endothelium, Vascular; Female; Humans; MCF-7 Cells; Mice, Nude; Microvessels; Neoplasm Proteins; Neovascularization, Pathologic; Paclitaxel; Receptors, Notch; RNA Interference; Signal Transduction; Specific Pathogen-Free Organisms; Taxoids; Xenograft Model Antitumor Assays

2016
Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.
    BMC cancer, 2016, 08-22, Volume: 16

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cdh1 Proteins; Cell Line, Tumor; Cisplatin; Cytokines; Endoglin; Female; Humans; Interferon-gamma; Interleukin-12 Subunit p35; Killer Cells, Natural; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-3

2016
Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.
    Oncotarget, 2016, 09-20, Volume: 7, Issue:38

    Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Perfusion; Receptor, Platelet-Derived Growth Factor beta; Tumor Microenvironment

2016
Knockdown of Hypoxia-Inducible Factor 1α Improved the Efficacy of Low-Dose Metronomic Chemotherapy of Paclitaxel in Human Colon Cancer Xenografts.
    Technology in cancer research & treatment, 2017, Volume: 16, Issue:5

    Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Neovascularization, Pathologic; Paclitaxel; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays

2017
Combined Tumor- and Neovascular-"Dual Targeting" Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis.
    ACS applied materials & interfaces, 2016, Oct-05, Volume: 8, Issue:39

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Mice; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel

2016
Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
    Biomaterials, 2017, Volume: 113

    Topics: Animals; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Breast; Breast Neoplasms; Drug Carriers; Drug Delivery Systems; Epithelial Cell Adhesion Molecule; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Rats, Sprague-Dawley

2017
Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
    Investigational new drugs, 2017, Volume: 35, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides; Tumor Burden

2017
MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Cancer letters, 2017, 02-01, Volume: 386

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; MicroRNAs; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptor, Notch3; Signal Transduction; Time Factors; Transfection

2017
Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-15, Volume: 14, Issue:14

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capillaries; Capillary Permeability; Cations; Cisplatin; Cricetinae; Liposomes; Male; Melanoma, Experimental; Mesocricetus; Neovascularization, Pathologic; Paclitaxel

2008
A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:12

    Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biological Assay; Blood Coagulation; Breast Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fibrin; Fluorouracil; Humans; Methotrexate; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Thrombin; Vincristine

2008
Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.
    Journal of cellular and molecular medicine, 2009, Volume: 13, Issue:10

    Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Situ Nick-End Labeling; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Subcutaneous Tissue; Xenograft Model Antitumor Assays

2009
Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
    Experimental biology and medicine (Maywood, N.J.), 2009, Volume: 234, Issue:10

    Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Immunohistochemistry; Liposomes; Lymph Nodes; Lymphatic Metastasis; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Tumor Burden; Vitamin E

2009
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
    Pharmacogenomics, 2009, Volume: 10, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; DNA; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genotype; Humans; Hypertension; Liver Neoplasms; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Polymorphism, Genetic; Vascular Endothelial Growth Factor A

2009
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.
    International journal of cancer, 2010, Mar-01, Volume: 126, Issue:5

    Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cisplatin; Cricetinae; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Gemcitabine; Humans; Immunohistochemistry; Lipopeptides; Liposomes; Lung Neoplasms; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms

2010
Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells.
    Oncology, 2009, Volume: 77, Issue:3-4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma 256, Walker; Cell Line; Cell Migration Inhibition; Cell Proliferation; Docetaxel; Endothelial Cells; Female; Humans; Neovascularization, Pathologic; Paclitaxel; Rats; Rats, Wistar; Stem Cells; Taxoids

2009
Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.
    Cancer gene therapy, 2010, Volume: 17, Issue:4

    Topics: Alphavirus Infections; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Membrane Permeability; Combined Modality Therapy; Cricetinae; Drug Delivery Systems; Female; Genetic Vectors; Humans; Mice; Mice, SCID; Neovascularization, Pathologic; Neuroblastoma; Oncolytic Virotherapy; Ovarian Neoplasms; Paclitaxel; Sindbis Virus; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
    Neoplasia (New York, N.Y.), 2009, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Piperidines; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays

2009
Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice.
    Cancer investigation, 2010, Volume: 28, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Female; Lymphangiogenesis; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Thrombospondin 1; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2

2010
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Cancer biology & therapy, 2010, Volume: 9, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Endothelium, Vascular; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Longitudinal Studies; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pericytes; Proto-Oncogene Proteins c-sis; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2010
Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
    Biomaterials, 2010, Volume: 31, Issue:8

    Topics: Aldehydes; Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Movement; Cells, Cultured; Drug Carriers; Drug Delivery Systems; Female; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Molecular Structure; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Particle Size; Peptides; Polyesters; Polyethylene Glycols; Polymers

2010
Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2010, Volume: 18, Issue:6

    Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Humans; Lymphocyte Depletion; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; T-Lymphocytes, Regulatory

2010
A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities.
    Biomaterials, 2010, Volume: 31, Issue:27

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Endocytosis; Endothelial Cells; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Nanocapsules; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Stilbenes

2010
Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
    Canadian journal of physiology and pharmacology, 2010, Volume: 88, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Xenograft Model Antitumor Assays

2010
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
    Oncology reports, 2010, Volume: 24, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide

2010
Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Availability; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Intestinal Absorption; Intestinal Mucosa; Isonicotinic Acids; Male; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Permeability; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays

2012
AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer.
    Gene therapy, 2011, Volume: 18, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Breast Neoplasms; Cells, Cultured; Endostatins; Endothelium, Vascular; Female; Genetic Therapy; Humans; Lung Neoplasms; Mice; Mutant Proteins; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Polyploidy; Recombinant Proteins

2011
Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor.
    Cancer research, 2010, Oct-01, Volume: 70, Issue:19

    Topics: Animals; Benzamides; Capillary Permeability; Carbon Isotopes; Humans; Hypoxia-Inducible Factor 1; Imatinib Mesylate; L-Lactate Dehydrogenase; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A

2010
In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
    Cancer immunology, immunotherapy : CII, 2011, Volume: 60, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Xenograft Model Antitumor Assays

2011
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
    Cancer research, 2011, Jan-15, Volume: 71, Issue:2

    Topics: Animals; Antigens, CD; Ascites; Cadherins; Cell Adhesion; Cell Line, Tumor; Drug Synergism; Endothelial Cells; Female; Humans; Interleukin-6; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Receptors, Interleukin-6; Recombinant Fusion Proteins; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays

2011
Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel.
    Biomaterials, 2011, Volume: 32, Issue:15

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cathepsin B; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Humans; Integrins; Mice; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyglutamic Acid; Rats; Rats, Wistar

2011
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Experimental biology and medicine (Maywood, N.J.), 2011, Volume: 236, Issue:7

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Mice; Mice, Nude; Naltrexone; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

2011
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.
    Blood, 2011, Sep-22, Volume: 118, Issue:12

    Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclams; Drug Combinations; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Immunohistochemistry; Inflammatory Breast Neoplasms; Injections, Intraperitoneal; Matrix Metalloproteinase 2; Mice; Mice, Knockout; Neovascularization, Pathologic; Paclitaxel; Receptors, CXCR4; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2011
Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy.
    Clinical & experimental metastasis, 2011, Volume: 28, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cachexia; Colonic Neoplasms; Dietary Fats; Dietary Supplements; Female; gamma-Glutamyltransferase; Mice; Mice, Inbred BALB C; Milk; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Soybean Oil; Time Factors

2011
A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Anticancer research, 2011, Volume: 31, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacterial Proteins; Bevacizumab; Cell Line, Tumor; Diphtheria Toxin; Female; Growth Inhibitors; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays

2011
Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Prognosis; Tomography, X-Ray Computed; Treatment Outcome

2012
The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel.
    Biomaterials, 2012, Volume: 33, Issue:8

    Topics: Animals; Carbocyanines; Cell Line; Cell Proliferation; Female; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Microscopy, Confocal; Microscopy, Electron, Transmission; Microvessels; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Particle Size; Peptides; Polymers; Tissue Distribution; Xenograft Model Antitumor Assays

2012
Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Mesenchymal Stem Cells; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Tumor Microenvironment; Xenograft Model Antitumor Assays

2011
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-15, Volume: 18, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays

2012
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    International journal of oncology, 2012, Volume: 40, Issue:5

    Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Corrosion Casting; Dose-Response Relationship, Drug; Female; Fluorescence; HEK293 Cells; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Phosphorylation; Receptor, TIE-2; Retinal Neovascularization; Time Factors; Transfection; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays

2012
Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
    International journal of cancer, 2012, Nov-15, Volume: 131, Issue:10

    Topics: Animals; Carcinoma; Cell Line, Tumor; Combined Modality Therapy; Female; Genetic Therapy; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays

2012
Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity.
    Journal of controlled release : official journal of the Controlled Release Society, 2012, Jun-28, Volume: 160, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cathepsin B; Cell Cycle; Cell Line, Tumor; Citrulline; Dipeptides; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Tumor Burden; Valine

2012
The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Aug-01, Volume: 18, Issue:15

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Female; Humans; Interferon-gamma; Interleukin-12; Mice; Mice, 129 Strain; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Recombinant Fusion Proteins; Single-Chain Antibodies; Tissue Distribution; Treatment Outcome; Tumor Burden

2012
Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:9

    Topics: Acetamides; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Drug Synergism; Estrogen Receptor alpha; Female; Focal Adhesion Kinase 1; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neoplasm Invasiveness; Neoplasm Micrometastasis; Neovascularization, Pathologic; Paclitaxel; Peptidomimetics; Pyridines; Pyrimidines; Receptor, ErbB-2; Receptors, Progesterone; src-Family Kinases; Thiazoles; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays

2012
Targeting angiogenesis in metastatic breast cancer.
    The oncologist, 2012, Volume: 17, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2012
Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:10

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Movement; Disease Models, Animal; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2012
Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416.
    Molecular pharmaceutics, 2012, Dec-03, Volume: 9, Issue:12

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Humans; Immunoenzyme Techniques; Indoles; Liposomes; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Pericytes; Polyethylene Glycols; Pyrroles; Solubility; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2

2012
Targeted delivery of paclitaxel to EphA2-expressing cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jan-01, Volume: 19, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Delivery Systems; Female; Gene Expression; Humans; Male; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Receptor, EphA2; Transplantation, Homologous; Tumor Burden; Xenograft Model Antitumor Assays

2013
Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
    Radiology, 2013, Volume: 266, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Breast Neoplasms; Capecitabine; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neovascularization, Pathologic; Paclitaxel; ROC Curve; Spectroscopy, Near-Infrared; Trastuzumab; Treatment Outcome; Ultrasonography, Interventional

2013
Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice.
    British journal of haematology, 2013, Volume: 160, Issue:6

    Topics: Animals; Cell Communication; Cell Growth Processes; Cell Line, Tumor; Disease Models, Animal; Humans; Leukemia; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays

2013
Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; bcl-X Protein; Blotting, Western; Bridged-Ring Compounds; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Division; Cell Nucleus; Cell Separation; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Growth Factors; Fibroblast Growth Factor 2; Flow Cytometry; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Maturation-Promoting Factor; Mitosis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Subcellular Fractions; Taxoids; Time Factors; Tubulin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
    Investigational new drugs, 2002, Volume: 20, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carboplatin; Cell Survival; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta; Regional Blood Flow; Transplantation, Heterologous

2002
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
    The American journal of pathology, 2002, Volume: 161, Issue:3

    Topics: Animals; Antineoplastic Agents; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured

2002
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10

    Topics: Androgens; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Disease Models, Animal; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
    Cancer research, 2002, Nov-15, Volume: 62, Issue:22

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Cell Division; Drug Synergism; Endothelin Receptor Antagonists; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays

2002
Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:13

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Movement; Cells, Cultured; Centrosome; Collagen; Docetaxel; Drug Combinations; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; In Vitro Techniques; Laminin; Mice; Mice, Inbred C57BL; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Proteoglycans; Rats; Taxoids; Tumor Cells, Cultured; Umbilical Veins; Xenograft Model Antitumor Assays

2002
Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:2

    Topics: Amides; Animals; Aorta, Thoracic; Cell Division; Cell Line; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, SCID; Microscopy, Fluorescence; Myosin-Light-Chain Phosphatase; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphoprotein Phosphatases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyridines; Rabbits; rho-Associated Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2003
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms

2003
Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.
    The Journal of investigative dermatology, 2003, Volume: 120, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Capsules; Cations; Cell Division; Endothelium, Vascular; Humans; Liposomes; Melanoma, Experimental; Mice; Mice, SCID; Mitotic Index; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured

2003
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Cancer research, 2003, May-15, Volume: 63, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Division; Drug Synergism; Endothelial Growth Factors; Endothelin Receptor Antagonists; Female; Growth Inhibitors; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays

2003
Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells.
    Journal of Asian natural products research, 2003, Volume: 5, Issue:2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion; Cell Movement; Chick Embryo; Collagenases; Humans; Melanoma, Experimental; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Tumor Cells, Cultured

2003
Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy.
    American journal of clinical oncology, 2003, Volume: 26, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Chemotaxis; Endothelial Cells; Humans; In Vitro Techniques; Mice; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Radiation-Sensitizing Agents; Rats; Rats, Sprague-Dawley

2003
Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Cancer, 2003, Oct-01, Volume: 98, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Probability; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Reference Values; Trastuzumab; Tumor Cells, Cultured

2003
Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
    Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:1

    Topics: Angiopoietin-1; Angiopoietin-2; Antineoplastic Agents, Phytogenic; Cell Division; Epithelium; Female; Gene Expression Regulation, Neoplastic; Humans; Neovascularization, Pathologic; Ovarian Neoplasms; Ovary; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2004
Taxol inhibits melanoma metastases through apoptosis induction, angiogenesis inhibition, and restoration of E-cadherin and nm23 expression.
    Journal of pharmacological sciences, 2003, Volume: 93, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cadherins; Coloring Agents; Eosine Yellowish-(YS); Fluorescent Dyes; Hematoxylin; Immunohistochemistry; In Situ Hybridization; In Situ Nick-End Labeling; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Electron; Neovascularization, Pathologic; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Paclitaxel; Protein Biosynthesis; RNA, Messenger; Vascular Endothelial Growth Factor A

2003
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-15, Volume: 9, Issue:15

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Fibroblast Growth Factor 2; Humans; Interleukin-8; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Models, Biological; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor A

2003
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
    Cancer research, 2004, Feb-01, Volume: 64, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Blood Proteins; Cell Division; Chemistry, Pharmaceutical; Docetaxel; Drug Interactions; Endothelium, Vascular; Excipients; Glycerol; Humans; In Vitro Techniques; Male; Neovascularization, Pathologic; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Protein Binding; Rats; Rats, Sprague-Dawley; Taxoids

2004
Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature.
    International journal of cancer, 2004, May-20, Volume: 110, Issue:1

    Topics: Animals; Cricetinae; Drug Carriers; Erythrocytes; In Situ Nick-End Labeling; Liposomes; Male; Melanoma, Experimental; Mesocricetus; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Regional Blood Flow

2004
Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2004, Volume: 112, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Body Weight; Male; Necrosis; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Rats; Vascular Endothelial Growth Factor A

2004
Angiogenesis gene expression profiling in xenograft models to study cellular interactions.
    Experimental cell research, 2004, Oct-01, Volume: 299, Issue:2

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Base Sequence; Disease Models, Animal; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Mice; Molecular Sequence Data; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Skin Neoplasms; Transplantation, Heterologous

2004
Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?
    Anti-cancer drugs, 2004, Volume: 15, Issue:9

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Administration Schedule; Female; Growth Inhibitors; Humans; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays

2004
Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:10

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Death; Cell Division; Cell Proliferation; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Endothelium, Vascular; G2 Phase; Humans; Intracellular Membranes; Laminin; Membrane Potentials; Microcirculation; Microscopy, Fluorescence; Microtubules; Mitochondria; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Time Factors

2004
Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer.
    Gynecologic oncology, 2004, Volume: 95, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Hemoglobins; Humans; Middle Aged; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Prognosis; Treatment Outcome

2004
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-01, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors

2005
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Cancer research, 2005, Feb-01, Volume: 65, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzimidazoles; Cell Growth Processes; Female; Glioblastoma; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Quinolines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Xenograft Model Antitumor Assays

2005
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.
    Cancer research, 2005, Mar-15, Volume: 65, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Microtubules; Neoplasms; Neovascularization, Pathologic; Paclitaxel

2005
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
    Cancer research, 2005, Apr-01, Volume: 65, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factors; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Paclitaxel; Xenograft Model Antitumor Assays

2005
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
    Journal of cardiovascular pharmacology, 2004, Volume: 44 Suppl 1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Line, Tumor; Cisplatin; Endothelin A Receptor Antagonists; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Time Factors; Xenograft Model Antitumor Assays

2004
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Umbilical Veins

2005
Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
    Cancer research, 2005, Jun-01, Volume: 65, Issue:11

    Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2

2005
Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    The Prostate, 2005, Nov-01, Volume: 65, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillary Permeability; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Purines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays

2005
Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
    International journal of oncology, 2005, Volume: 27, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Green Fluorescent Proteins; Humans; Immunohistochemistry; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Peritoneal Neoplasms; Plasmids; Platelet Endothelial Cell Adhesion Molecule-1; Stomach Neoplasms; Survival Analysis; Survival Rate; Transfection; Treatment Outcome; Xenograft Model Antitumor Assays

2005
Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    BJU international, 2005, Volume: 96, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Drug Administration Schedule; Drug Synergism; Fluorescent Antibody Technique; Imatinib Mesylate; Male; Mice; Mice, SCID; Models, Animal; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Treatment Failure

2005
Albumin-bound nanoparticle paclitaxel.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:5

    Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Nanostructures; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Prodrugs

2005
Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.
    PLoS medicine, 2005, Volume: 2, Issue:12

    Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Biopsy; Dose-Response Relationship, Drug; Female; Fibrosis; Humans; Male; Mice; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Phenotype; Scleroderma, Systemic; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Transplantation, Heterologous

2005
YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors.
    Biological & pharmaceutical bulletin, 2005, Volume: 28, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Mice; Mice, Nude; Morpholines; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Quinolines; Vascular Endothelial Growth Factor Receptor-2

2005
Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice.
    Journal of controlled release : official journal of the Controlled Release Society, 2005, Dec-10, Volume: 110, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Diffusion; Drug Carriers; Drug Stability; Endothelial Cells; Hydrogels; Injections, Subcutaneous; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Photochemistry; Skin Neoplasms

2005
The inhibition of angiogenesis by antisense oligonucleotides to clusterin.
    Angiogenesis, 2005, Volume: 8, Issue:3

    Topics: Apoptosis; Base Sequence; bcl-X Protein; Camptothecin; Cell Line; Cell Survival; Clusterin; Collagen; DNA Fragmentation; Doxorubicin; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Humans; Inhibitor of Apoptosis Proteins; Laminin; Microtubule-Associated Proteins; Neoplasm Proteins; Neovascularization, Pathologic; Oligonucleotides, Antisense; Paclitaxel; Proteoglycans; Survivin; Thionucleotides

2005
[Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice].
    Chinese medical journal, 2005, Oct-20, Volume: 118, Issue:20

    Topics: Animals; Antigens, CD34; Cell Line, Tumor; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Transplantation, Heterologous

2005
Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging.
    Cancer biology & therapy, 2006, Volume: 5, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Capsules; Contrast Media; Cricetinae; Gadolinium DTPA; Lipids; Magnetic Resonance Imaging; Melanoma; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured

2006
EndoTAG-1. MediGene.
    Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:12

    Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Liposomes; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms

2005
Antitumor effects of IDN5109 on head and neck squamous cell carcinoma.
    Oncology reports, 2006, Volume: 15, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Neovascularization, Pathologic; Paclitaxel; Taxoids

2006
Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-01, Volume: 12, Issue:1

    Topics: Alkanes; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Caspases; Cell Cycle; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Female; Humans; Immunohistochemistry; Lactones; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Pyrones; Xenograft Model Antitumor Assays

2006
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Thiazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2006
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-15, Volume: 12, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Line, Tumor; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Female; Immunohistochemistry; Indoles; Laminin; Mice; Mice, Nude; Myocytes, Smooth Muscle; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxindoles; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Proteoglycans; Pyrroles; Xenograft Model Antitumor Assays

2006
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:6

    Topics: Angiostatins; Animals; Antineoplastic Agents; Cell Line, Tumor; Clonal Anergy; Cyclohexanes; Cyclophosphamide; Down-Regulation; Endostatins; Endothelial Cells; Endothelium; Humans; Intercellular Adhesion Molecule-1; Leukocytes; Mice; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Peptides; Proteins; Sesquiterpenes; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2006
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Journal of the National Cancer Institute, 2006, Jun-07, Volume: 98, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tibia; Tumor Cells, Cultured

2006
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-15, Volume: 12, Issue:14 Pt 1

    Topics: Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Bridged-Ring Compounds; Cell Proliferation; Endothelium, Vascular; Female; Humans; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Rats; Surface-Active Agents; Taxoids

2006
Is it time for some new approaches for treating advanced ovarian cancer?
    Journal of the National Cancer Institute, 2006, Aug-02, Volume: 98, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Failure

2006
[Combined low-dose chemotherapy inhibiting angiogenesis and growth of Lewis lung cancinoma xenografts in mice].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2006, Volume: 37, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cyclophosphamide; Female; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Paclitaxel; Random Allocation; Vascular Endothelial Growth Factor A

2006
Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity?
    Gynecologic oncology, 2007, Volume: 104, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neovascularization, Pathologic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A

2007
Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
    International journal of oncology, 2006, Volume: 29, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Breast Neoplasms; Cell Growth Processes; Chick Embryo; Collagen Type IV; Dose-Response Relationship, Immunologic; Drug Synergism; Epitopes; Extracellular Matrix; Female; Humans; Immunoglobulin G; Immunoglobulin M; Male; Melanoma; Mice; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1

2006
Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2007, Volume: 15, Issue:1

    Topics: Animals; Apoptosis; Cells, Cultured; Drug Therapy, Combination; Electrophysiology; Endothelial Cells; Humans; Injections, Intramuscular; Lectins; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Paclitaxel; Peripheral Nervous System Diseases; Phosphatidylinositol 3-Kinases; Plasmids; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Renal Circulation; Thalidomide; Vasa Nervorum; Vascular Endothelial Growth Factor A

2007
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Feb-20, Volume: 104, Issue:8

    Topics: Animals; Antibodies; Antibody Formation; Cancer Vaccines; Cell Line, Tumor; Colorectal Neoplasms; Female; HT29 Cells; Humans; Immune Sera; Immunization; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Rhabdomyosarcoma; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2007
Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
    Human cell, 2007, Volume: 20, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Tetrazoles; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2007
Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
    Oncology reports, 2007, Volume: 18, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2007
Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
    International journal of oncology, 2007, Volume: 31, Issue:1

    Topics: Animals; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin D1; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neovascularization, Pathologic; Oligodeoxyribonucleotides; Paclitaxel; Phosphorylation; Protein Conformation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; STAT3 Transcription Factor; Survivin; Vascular Endothelial Growth Factor A

2007
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endothelin A Receptor Antagonists; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Xenograft Model Antitumor Assays

2007
Endostatin gene therapy enhances the efficacy of paclitaxel to suppress breast cancers and metastases in mice.
    Journal of biomedical science, 2008, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Chick Embryo; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Endostatins; Female; Gene Expression; Genetic Therapy; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Paclitaxel; Recombinant Proteins

2008
Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
    British journal of cancer, 2007, Oct-08, Volume: 97, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mice; Mice, Nude; Mitosis; Necrosis; Neovascularization, Pathologic; Organophosphorus Compounds; Paclitaxel; Survival Rate; Treatment Outcome; Xenograft Model Antitumor Assays

2007
[Inhibitory effect of huangqi and dangshen extraction with pacilitaxel on metastasis and angiogenesis on mouse Lewis lung carcinoma model].
    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2008, Volume: 24, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Codonopsis; Drugs, Chinese Herbal; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel

2008
Taxol and embryonic development in the chick.
    Teratogenesis, carcinogenesis, and mutagenesis, 1994, Volume: 14, Issue:1

    Topics: Abnormalities, Drug-Induced; Animals; Chick Embryo; Dose-Response Relationship, Drug; Neovascularization, Pathologic; Paclitaxel; Time Factors

1994
Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol.
    Cellular immunology, 1994, Volume: 157, Issue:1

    Topics: Animals; Antibody Formation; Arthritis, Experimental; Autoimmune Diseases; Collagen; Cyclohexanes; Drug Therapy, Combination; Female; Immunity, Cellular; Microtubules; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Rats; Sesquiterpenes

1994
Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid).
    Cancer letters, 1995, Jan-06, Volume: 88, Issue:1

    Topics: Animals; Chick Embryo; Delayed-Action Preparations; In Vitro Techniques; Lactates; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Neovascularization, Pathologic; Paclitaxel; Polymers; Polyvinyls

1995
Taxol encapsulation in poly(epsilon-caprolactone) microspheres.
    Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:4

    Topics: Allantois; Animals; Chick Embryo; Chorion; Delayed-Action Preparations; Microspheres; Neovascularization, Pathologic; Paclitaxel; Polyesters

1995
Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
    Journal of cancer research and clinical oncology, 1996, Volume: 122, Issue:9

    Topics: Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genes, p53; Genes, Tumor Suppressor; Humans; Hyperplasia; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Research; Survival Rate

1996
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Carcinoma, Lewis Lung; Cell Survival; Colony-Forming Units Assay; Cyclohexanes; Drug Synergism; Drug Therapy, Combination; Female; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Minocycline; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes

1998
Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization.
    Clinical immunology and immunopathology, 1998, Volume: 86, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Arthritis, Rheumatoid; Collagen; Corrosion Casting; Disease Models, Animal; Female; Humans; Microscopy, Electron; Microscopy, Electron, Scanning; Neovascularization, Pathologic; Paclitaxel; Rats; Rats, Inbred Strains; Synovial Membrane; Synovitis

1998
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Movement; Cells, Cultured; Cisplatin; Collagen; Drug Combinations; Endothelium, Vascular; Laminin; Male; Mice; Mice, Inbred C57BL; Microtubules; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Proteoglycans

1996
Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes.
    Drug metabolism and disposition: the biological fate of chemicals, 1999, Volume: 27, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cells, Cultured; Cyclohexanes; Cyclophosphamide; Drug Interactions; Liver; Macaca mulatta; Microsomes, Liver; Minocycline; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Tissue Distribution

1999
Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Organic Chemicals; Paclitaxel; Transplantation, Heterologous; Treatment Outcome; Tumor Cells, Cultured

1999
[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
    Mund-, Kiefer- und Gesichtschirurgie : MKG, 1999, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillaries; Carcinoma, Squamous Cell; Docetaxel; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Taxoids; Tumor Cells, Cultured

1999
Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Cyclin-Dependent Kinase Inhibitor p27; Female; Growth Substances; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotides, Antisense; Paclitaxel; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins

2000
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Endothelial Growth Factors; Fibroblast Growth Factor 2; Humans; Interleukin-8; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Microcirculation; Neovascularization, Pathologic; Paclitaxel; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays

2000
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:12

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Cetuximab; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Down-Regulation; Endothelial Growth Factors; Endothelium; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Inhibitory Concentration 50; Interleukin-8; Lymphatic Metastasis; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Neoplasm Transplantation; Neovascularization, Pathologic; Organ Size; Paclitaxel; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2000
Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
    Cancer letters, 2001, Feb-26, Volume: 163, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endothelial Growth Factors; Female; Humans; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; RNA, Messenger; Thalidomide; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001
Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma.
    The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Division; Cell Hypoxia; Cell Movement; Cell Survival; Drug Synergism; Endothelial Growth Factors; Endothelium, Vascular; Humans; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Polyenes; Polyunsaturated Alkamides; Thyroid Neoplasms; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001
Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy.
    American journal of clinical oncology, 2001, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carboplatin; Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tumor Suppressor Protein p53

2001
Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.
    The Annals of thoracic surgery, 2001, Volume: 72, Issue:2

    Topics: Allylamine; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Benzothiazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Synergism; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Lactams, Macrocyclic; Lung Neoplasms; Lymphokines; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Quinones; Tumor Cells, Cultured; Tyrphostins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:9

    Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Biopsy; Blood Vessels; Blotting, Northern; Cadherins; Carcinoma, Transitional Cell; Cell Movement; Collagen; Collagenases; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Interferon-alpha; Interleukin-8; Laminin; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Prognosis; Proteoglycans; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays

2001
Biological basis for chemo-radiotherapy interactions.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids

2002
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
    Cancer research, 2002, Feb-01, Volume: 62, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Breast Neoplasms; Cell Movement; Coumarins; Cyclophosphamide; Drug Synergism; Endothelium, Vascular; Female; Fluorouracil; Growth Inhibitors; Humans; Isocoumarins; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays

2002
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.
    Nature medicine, 2002, Volume: 8, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Endothelial Growth Factors; Endothelium, Vascular; Extraembryonic Membranes; Female; Fibroblast Growth Factor 2; HIV Protease Inhibitors; Humans; Indinavir; Lymphokines; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Saquinavir; Sarcoma, Kaposi; Skin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Quantitative analysis of angiogenesis using confocal laser scanning microscopy.
    Angiogenesis, 2001, Volume: 4, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Capillaries; Carcinoma, Non-Small-Cell Lung; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Muscle, Skeletal; Neoplasm Transplantation; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Xenograft Model Antitumor Assays

2001
Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5

    Topics: Androgens; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blood Vessels; Cell Cycle Proteins; Cell Division; Cetuximab; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Interleukin-8; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Prostatic Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins; Tyrosine; Up-Regulation; Xenograft Model Antitumor Assays

2002
Assessment of antiangiogenic effect using 99mTc-EC-endostatin.
    Cancer biotherapy & radiopharmaceuticals, 2002, Volume: 17, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Collagen; Cysteine; Endostatins; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lymphokines; Mammary Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Peptide Fragments; Radionuclide Imaging; Rats; Rats, Inbred F344; Technetium; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
A mouse model for the study of factors affecting angiogenesis.
    Pharmacology & toxicology, 2002, Volume: 90, Issue:3

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Docetaxel; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Humans; Ifosfamide; Injections, Subcutaneous; Mice; Neovascularization, Pathologic; Paclitaxel; Prostheses and Implants; Surgical Sponges; Taxoids

2002